Nonresectable hepatocellular carcinoma: Long-term toxicity in patients treated with transarterial chemoembolization - Single-center experience

被引:50
|
作者
Buijs, Manon [1 ]
Vossen, Josephina A. [1 ]
Frangakis, Constantine [1 ]
Hong, Kelvin [1 ]
Georgiades, Christos S. [1 ]
Chen, Yong [1 ]
Liapi, Eleni [1 ]
Geschwind, Jean-Francois H. [1 ]
机构
[1] Johns Hopkins Univ Hosp, Div Vasc & Intervent Radiol, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21287 USA
关键词
D O I
10.1148/radiol.2483071902
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To determine the toxicity profile of transarterial chemoembolization (TACE) at 6 months and 1 year after treatment in patients with hepatocellular carcinoma (HCC) in a standardized oncology protocol so that TACE could be compared with systemic chemotherapeutic regimens for liver cancer. Materials and Methods: The study was authorized by the institutional review board. Between January 2002 and January 2007, 190 patients (155 men, 35 women; median age, 65 years; age range, 18-84 years) with HCC who underwent TACE treatment were identified from a prospectively collected database. Clinical records of complete blood cell counts and chemical profiles at baseline and at 6 and 12 months after treatment were studied retrospectively. Toxicity was graded according to the common terminology criteria for adverse events (CTCAE). A transition ( survival) analysis perspective was used to estimate the distribution of toxicity grades. Patient survival from the first TACE session was calculated with Kaplan-Meier analysis. Results: Grade 3 or 4 toxicity 6 and 12 months, respectively, after treatment included leukocytopenia (7% and 19%); anemia (9% and 19%); thromobocytopenia (13% and 23%); prolonged activated partial thromboplastin time (8% and 18%); elevated aspartate aminotransferase (15% and 18%), alanine aminotransferase (10% and 18%), and alkaline phosphatase (8% and 18%) levels; hypoalbuminemia (10% and 19%); hyperbilirubinemia (10% and 22%); and alopecia (18%). The cumulative survival rate was 58% at 1 year, 39% at 2 years, and 29% at 3 years. These toxicity rates were considerably lower than those reported after treatment with currently used systemic chemotherapeutic agents. Conclusion: Study results show that TACE has a favorable long-term toxicity profile in patients with HCC. Data clearly support the role of TACE in the treatment of patients with nonresectable HCC. (c) RSNA, 2008.
引用
收藏
页码:346 / 354
页数:9
相关论文
共 50 条
  • [1] Transarterial chemoembolization for treatment of hepatocellular carcinoma: A single center experience
    Idilman, Ilkay
    Peynircioglu, Bora
    Cil, Barbaros Erhan
    Erdogan, Beyza Doganay
    Yalcin, Suayip
    Bayraktar, Yusuf
    Kav, Taylan
    Altundag, Kadri
    Balkanci, Ferhun
    [J]. TURKISH JOURNAL OF GASTROENTEROLOGY, 2013, 24 (02): : 141 - 147
  • [2] Efficacy of Transarterial Chemoembolization with Drug-Eluting Beads in Hepatocellular Carcinoma: A Single-Center Experience
    Danisan, Gurkan
    Arik, Erbil
    [J]. DUZCE MEDICAL JOURNAL, 2022, 24 (02) : 105 - 109
  • [3] Transarterial Chemoembolization before Liver Transplantation in Patients with Hepatocellular Carcinoma - a Single Center Experience
    Liese, J.
    Moench, C.
    Schreckenbach, T.
    Sarrazin, C. M.
    Zeuzem, S.
    Zangos, S.
    Vogl, T.
    Bechstein, W. O.
    Ulrich, F.
    [J]. TRANSPLANTATION, 2012, 94 (10) : 636 - 636
  • [4] Transarterial chemoembolization for the treatment of hepatocellular carcinoma: A single center experience including 221 patients
    Zeeneldin, Ahmed Abdelmabood
    Salem, Salem Eid
    Tabashy, Reda Hassan
    Ibrahim, Asmaa Ahmed
    Alieldin, Nelly Hassan
    [J]. JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2013, 25 (03) : 143 - 150
  • [5] Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience
    Dominik Bettinger
    Renan Spode
    Nicolas Glaser
    Nico Buettner
    Tobias Boettler
    Christoph Neumann-Haefelin
    Thomas Baptist Brunner
    Eleni Gkika
    Lars Maruschke
    Robert Thimme
    Michael Schultheiss
    [J]. BMC Gastroenterology, 17
  • [6] Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience
    Bettinger, Dominik
    Spode, Renan
    Glaser, Nicolas
    Buettner, Nico
    Boettler, Tobias
    Neumann-Haefelin, Christoph
    Brunner, Thomas Baptist
    Gkika, Eleni
    Maruschke, Lars
    Thimme, Robert
    Schultheiss, Michael
    [J]. BMC GASTROENTEROLOGY, 2017, 17
  • [7] Long-term survival after transarterial chemoembolization for hepatocellular carcinoma
    Iozzino, M.
    Spaziani, E.
    Picchio, M.
    Saltarelli, A.
    Di Filippo, A.
    De Angelis, F.
    Narilli, F.
    Stagnitti, F.
    Cianni, R.
    [J]. CLINICA TERAPEUTICA, 2011, 162 (02): : 129 - 132
  • [8] Transarterial chemoembolization extends long-term survival in patients with unresectable hepatocellular carcinoma
    Kong, Jie-Yu
    [J]. MEDICINE, 2018, 97 (33)
  • [9] Balloon-Occluded Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma: A Single-Center US Preliminary Experience
    Goldman, Daryl T.
    Singh, Manu
    Patel, Rahul S.
    Nowakowski, F. Scott
    Bishay, Vivian
    Ranade, Mona
    Lookstein, Robert A.
    Fischman, Aaron M.
    [J]. JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2019, 30 (03) : 342 - 346
  • [10] Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: A single-center experience
    Mazzarelli, C.
    Costantino, D.
    Cesarini, L.
    Zavaglia, C.
    Rampoldi, A.
    Morelli, F.
    Cabrini, G.
    Capitanio, S.
    Zanni, D.
    Carboni, C.
    Belli, L. S.
    [J]. DIGESTIVE AND LIVER DISEASE, 2023, 55 : S68 - S68